



Divi's Laboratories Limited

April 18, 2025

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
Mumbai – 400 051

To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai – 400 001

Trading Symbol: **DIVISLAB**

Scrip Code: **532488**

Dear Sir / Madam,

Sub: Intimation of signing of long-term manufacturing and supply agreement

Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby submit the details as required under Para B of Part A of Schedule III of the Regulations read with Circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Sl. No	Particulars	Details
1.	Name of the entity with whom agreement is signed	A global pharma company
2.	Area of agreement	Long-term manufacturing and supply agreement
3.	Domestic/International	International
4.	Share exchange ratio	Not applicable
5.	Scope of business operation of agreement	Manufacturing and supply of advanced intermediates.
6.	Details of consideration paid / received in agreement	There is no upfront payment involved in this agreement.
7.	Significant terms and conditions of agreement in brief	<ul style="list-style-type: none">• Under the long-term agreement, the Company will be manufacturing and supplying advanced intermediates as per the commercial terms agreed between the parties.• The Company expects meaningful revenue contribution from this long-term agreement.• In view of the confidentiality agreement signed, we are not permitted to disclose name of customer and any quantitative information pertaining to the agreement.

Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA.

Tel : +91-40-6696 6300/400, Fax : 91-40-6696 6460., CIN : L24110TG1990PLC011854

E-mail : mail@divislabs.com, Website : www.divislabs.com



Divi's Laboratories Limited

		<ul style="list-style-type: none">The Company is planning for capacity addition at its manufacturing facilities with an estimated investment between ₹650 crores to ₹700 crores, to be funded from internal accruals.
8.	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	Not applicable
9	Size of the entity(ies)	Not applicable
10	Rationale and benefit expected	The Agreement will benefit the customer of assured supply and the Company to expand its presence in custom synthesis.

This is for your information and records.

Thanking You,

Yours faithfully,

For Divi's Laboratories Limited

M. Satish Choudhury
Company Secretary & Compliance Officer